A Phase 2 interventional study of Stereotactic Radiosurgery and Stereotactic Radiosurgery in Essential Tremor, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 1 site in Poland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Phase 2, Interventional, and Treatment
The goal of this interventional study is to evaluate the effectiveness of treatment using stereotactic radiosurgery in the treatment of essential tremor in adult patients
The study will include patients diagnosed with essential tremor who have insufficient tremor control despite the use of available pharmacotherapy methods. The study will include patients who have been disqualified from the Deeply Brain Stimulation procedure or who do not consent to its performance. Additional conditions for the examination are age over 50 and the duration of the disease over 5 years.
After qualifying and giving written informed consent, the patient will be randomly assigned to one of two study arms:
The primary aim of the study is to determine the effectiveness of radiosurgery in patients with essential tremor. Secondary objectives will be to determine the impact of treatment on the quality of life of, as well as to assess the safety and possible complications of radiosurgery.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
This study's planned enrollment of 42 is above the median of 25 across 189 interventional studies indexed under Essential Tremor.
Browse Essential Tremor studies →Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients irradiated with the CyberKnife with a dose of 130 Gy
Radiation: Stereotactic Radiosurgery
Patients irradiated with the CyberKnife with a dose of 80 Gy
Radiation: Stereotactic Radiosurgery
Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 80 Gy
Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 130 Gy
Treatment Efficacy
Efficacy of radiosurgery treatment in patients with essential tremor assessed on a dedicated tremor severity scale - Fahn-Tolosa-Marin (FTM)
Time frame: 24 months
Quality of life
The impact of treatment on the quality of life of patients based on the dedicated Quality of Life in Essential Tremor questionnaire
Time frame: 24 months
Safety
Safety and possible complications of radiosurgery assesed in Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: 24 months
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for May 2030, 64 months after the start.
Of 20 phase 2 interventional studies under Essential Tremor, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 64 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maria Sklodowska-Curie National Research Institute of Oncology